BridgeMD
New treatment option for Depression
Official title Improvement of Depression With Use of ATP
ClinicalTrials.gov ID: NCT06266715
What this study is testing
What is ATP Group?
ATP Group is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for depression.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This clinical study is a randomized, double-blind, placebo-controlled trial with an intervention period of 4 weeks. Participants will be patients with moderate to severe depression who meet the inclusion criteria during the screening period.
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Meet the diagnostic and statistical manual of mental disorders-5 diagnostic criteria for moderate to severe depression.
- HAMD-24 scores ≥ 20.
- 18-65 female or male.
- Participants who have not used any psychotropic medications within one month prior to study and never had a treatment with escitalopram.
- Individuals without contraindications to selective serotonin reuptake inhibitor.
You likely can't join if
- Participants with various major mental disorders other than depression (bipolar disorder, any psychotic disorder, Personality Disorders, alcohol use...
- Individuals with neurological disorders such as dementia.
- Individuals with a high risk of suicide.
- Pregnant and lactating women.
- Contraindications to MRI.
- Physician evaluation was not suitable for participants in this study.
See the full eligibility criteria
- Meet the diagnostic and statistical manual of mental disorders-5 diagnostic criteria for moderate to severe depression.
- HAMD-24 scores ≥ 20.
- 18-65 female or male.
- Participants who have not used any psychotropic medications within one month prior to study and never had a treatment with escitalopram.
- Individuals without contraindications to selective serotonin reuptake inhibitor.
- Individuals without contraindications to ATP.
- Written informed consent.
- Participants with various major mental disorders other than depression (bipolar disorder, any psychotic disorder, Personality Disorders, alcohol use disorder, substance use disorder, and disorders due to medical or...
- Individuals with neurological disorders such as dementia.
- Individuals with a high risk of suicide.
- Pregnant and lactating women.
- Contraindications to MRI.
- Physician evaluation was not suitable for participants in this study.
The study team makes the final eligibility decision.
Where it's taking place
- Guangzhou, Guangdong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guangzhou, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.